The Wheel Strategy on BABA (Alibaba): The Honest China ADR Guide
What's in this guide
1. Should you wheel BABA at all? 2. The real risks — China + delisting + concentration 3. Why BABA can still make sense (occasionally) 4. Strike selection on BABA (very conservative) 5. Position sizing — smaller than normal 6. A worked example — full cycle with what could go wrong 7. Special considerations 8. Next stepsBABA (Alibaba) is China's largest e-commerce and cloud company, listed in the US as an American Depositary Receipt. For wheelers, BABA has an unusual profile: elevated IV (~35-50%) meaning meaningful premium capture, but two specific risks that most stocks don't have — Chinese regulatory intervention (which erased 70% of BABA's value in 2020-2022) and US delisting threats (SEC oversight requirements).
This guide walks through the honest playbook — including why most wheelers should skip BABA entirely.
1. Should you wheel BABA at all?
BABA fails several standard quality tests for wheelers:
- Regulatory intervention risk: Chinese government has demonstrably destroyed BABA's stock (Ant Financial IPO block 2020, antitrust fines, algorithmic regulation)
- US delisting threat: HFCAA (Holding Foreign Companies Accountable Act) creates ongoing delisting risk if PCAOB audit access is restricted
- No US shareholder protections: BABA ADRs are actually shares of a Cayman Islands VIE (Variable Interest Entity) — you don't own actual Alibaba stock
- Currency + capital flow risk: Chinese capital controls could restrict cash flows to ADR holders
Most wheelers should not wheel BABA. The elevated IV premium doesn't adequately compensate for the tail risks. Better quality-name alternatives exist.
2. The real risks — China + delisting + concentration
- Chinese regulatory intervention: demonstrated willingness to intervene (Ant Financial 2020 IPO cancellation, $2.8B antitrust fine, algorithm regulation)
- US delisting: ongoing risk if PCAOB audit access is restricted or geopolitical tensions escalate
- VIE structure risk: Chinese government has never explicitly blessed VIE structures used by BABA and others
- Chinese consumer weakness: ~60%+ of revenue from Chinese consumer commerce; economic slowdown = revenue pressure
- Local competition: PDD (Pinduoduo/Temu), JD.com, Douyin all taking share
3. Why BABA can still make sense (occasionally)
- Fat premium from elevated IV (~35-50%) — if you understand and accept the risks
- Underlying business is strong — Alibaba Cloud, Taobao, Tmall, international expansion
- Extreme discount valuation — trades at deep multiple discount vs US tech peers
- Deep options liquidity — one of the most-traded ADRs
- Post-crisis normalization opportunity — if China regulatory environment stabilizes
4. Strike selection on BABA (very conservative)
| Situation | Suggested delta | DTE |
|---|---|---|
| Normal conditions | 0.12-0.15 delta | 30-45 DTE |
| Elevated IV (regulatory news) | 0.10-0.12 delta | 30-45 DTE |
| Low IV (rare) | 0.15-0.20 delta | 30 DTE |
| Post-regulatory intervention | Wait for stabilization | Post-news |
Note: BABA deltas should be roughly HALF what you'd use on quality US names. The tail risk requires deeper OTM strikes.
5. Position sizing — smaller than normal
BABA at $120 requires $12,000 per contract. Sizing rules:
- Max 5-10% of wheel capital in BABA specifically (half or less than normal)
- Never combine BABA with other Chinese ADRs (JD, PDD, BIDU) — Chinese concentration risk
- Keep 40%+ cash cushion when holding BABA positions
- Prefer 1 contract only regardless of account size
- Never hold BABA in a Roth IRA — capital tied up in Chinese ADR is bad fit for tax-free growth vehicle
6. A worked example — with what could go wrong
BABA at $120, IV rank 55. You have $12,000 for this position, using conservative 0.13 delta:
| Day | Action | Result | Cumulative P/L |
|---|---|---|---|
| 0 | Sell 1 BABA $105P, 35 DTE, 0.13 delta | Collect $250 premium | +$250 |
| 22 | Put worth $120 (52% profit). Buy to close. | Free capital. | +$130 net |
| 22 | Sell 1 BABA $107P, 35 DTE, 0.13 delta | Collect $265 premium | +$395 |
| 57 | BABA at $125 at expiration; put expired worthless. | Kept full $265. | +$395 |
Best case: $395 on $12,000 in 2 months = ~3.3% for cycle. Not spectacular for the risk taken.
Worst-case scenario: Chinese regulator announces new algorithmic content restrictions. BABA drops from $120 to $85 in 3 days. Put strike $105 is now $20 ITM. Put worth ~$2,000. You either take assignment at $105 on stock trading $85 (~$2,000 loss), OR close at ~$1,700 loss. And if the crisis deepens (2021-style), further 30-50% drops possible.
7. Special considerations
No dividend
BABA pays no dividend. No income during assignment periods. CC premium is sole income if assigned. Combined with tail risk = challenging profile.
US-China trade + geopolitical events
BABA reacts to trade tension news, TikTok bans, Taiwan tensions, and other US-China diplomatic developments. Very volatile on such news.
Earnings + Chinese economic data
BABA earnings can move 5-15% on Chinese consumer commerce data, cloud growth, or forward guidance. Chinese GDP + retail sales data also material.
8. Next steps
- Seriously consider skipping BABA entirely — better wheels exist elsewhere
- If you proceed, use 0.10-0.15 delta only and max 5-10% of wheel capital
- Never wheel BABA in a Roth IRA
- Monitor Chinese regulatory news + US-China tensions closely
- Have a plan for extended assignment — no dividend, potential 30-50% additional drops
For real weekly wheel trades I run in my own account (mostly quality US names, rarely BABA in specific circumstances), the Omega Membership shares the trade plan. Or grab the free Starter Kit.
Ready to shadow real wheel trades?
The Omega Membership is the weekly trade plan I run in my own account — Sunday market prep, live calls, and the members' Discord.
See the membership → Free Starter KitFrequently asked questions
Should I wheel BABA (Alibaba)?
Most wheelers should skip BABA. Chinese regulatory intervention risk (2020-2022 lost 70% of value), US delisting threats, VIE structure risk, and no US shareholder protections make BABA a specialized wheel. Elevated IV premium (~35-50%) doesn't adequately compensate for tail risks. Only wheel BABA if you have specific thesis and understand these risks.
Why is BABA considered risky for the wheel strategy?
Five specific risks: (1) Chinese regulatory intervention (demonstrated willingness — Ant IPO cancellation, antitrust fines, algorithm regulation), (2) US delisting threat from HFCAA if PCAOB audit access restricted, (3) VIE structure — BABA ADRs are actually Cayman Islands shell shares, (4) Chinese consumer weakness, (5) local competition from PDD/JD.com/Douyin.
What delta should I use for BABA puts?
0.10-0.15 delta — roughly HALF what you'd use on quality US names (0.20-0.25). Tail risk from regulatory intervention requires deeper OTM strikes. Drop to 0.10-0.12 delta if IV is elevated during Chinese regulatory news cycles.
How much capital should I allocate to BABA?
Max 5-10% of wheel capital (half or less than normal 20%). Prefer 1 contract only regardless of account size. Keep 40%+ cash cushion when holding BABA. Never combine with other Chinese ADRs (JD, PDD, BIDU) — Chinese concentration risk.
Should I wheel BABA in a Roth IRA?
No. Roth IRA is for tax-free compounding over decades. BABA's tail risk (regulatory intervention, delisting) and no-dividend profile don't fit that mission. Additionally, no US shareholder protections mean capital could be at risk in ways US stocks aren't. Skip BABA in tax-advantaged accounts.
What happened to BABA in 2020-2022 that made it risky?
Multiple Chinese regulatory interventions: (1) November 2020 — Ant Financial IPO cancelled 48 hours before listing, (2) 2021 — $2.8B antitrust fine, (3) 2021-2022 — algorithm regulation restricting content recommendations, (4) 2021-2022 — for-profit tutoring crackdown showing government willingness to destroy entire industries. BABA lost ~70% of value peak-to-trough.
When would BABA actually work for the wheel?
Four specific scenarios: (1) post-crisis moments when IV is genuinely elevated compensating for actual increased risk, (2) you're willing to accept assignment and hold for years, (3) you're sizing significantly smaller than normal (5-10% max), (4) you have specific thesis on China regulatory stabilization. Missing any = skip.
What if I get assigned on BABA?
Prepare for potentially deeper drops. No dividend to soften wait. Chinese regulatory intervention can cause 20-30% additional drops. Sell CCs conservatively (at cost basis or above only). Consider: is your thesis still intact? Regulatory intervention may permanently change the business. Consider closing at loss if regulatory environment worsens materially.